Long-term effects of testosterone therapy on prostate volume and LUTS in hypogonadal men: a retrospective study
Scandinavian Journal of Urology · 2026
DOI: 10.2340/sju.v61.45576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Urology, 2026. Verfasst von Peter Ströberg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Urohälsan i Skövde, Skövde, Sweden; Department of Urology Region Jönköpings län, Jönkoping, Sweden. Hauptthemen laut MEDLINE: Testosterone, Lower Urinary Tract Symptoms, Prostate, Prostatic Hyperplasia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Up to 20% of aging men have low serum testosterone (late-onset hypogonadism [LOH]), and approximately 80% develop benign prostatic enlargement (BPE) with increasing age. Both age and prostate size are linked to lower urinary tract symptoms (LUTS). This study aimed to evaluate the effect of testosterone replacement therapy (TRT) on prostate volume and LUTS in men with LOH. Materials and methods: From 2004 to 2017, 511 men underwent annual checkups including physical examination, transrectal ultrasound, bladder scanning, serum Prostate-Specific Antigen (s-PSA), and serum testosterone and questionnaires on LUTS and LOH symptoms. None had prior treatments affecting prostate size or LUTS at baseline. During the annual follow-ups, 167 men (33%) were diagnosed with symptomatic LOH and received TRT. A longitudinal statistical model was used to compare periods with and without treatment regarding prostate growth, post-void residual urine, IPSS (International Prostate Symptom Score), quality of life (QoL), and s-PSA.
Results
Participants contributed 3745 visits (median 7 per man), including 904 (24%) after testosterone initiation. TRT was associated with a mean increase in prostate growth rate of 0.22 mL/year compared with untreated periods (p = 0.023). No significant differences were observed in LUTS, QoL, or s-PSA between treated and untreated periods Conclusion: In ageing males with late-onset hypogonadism, testosterone replacement therapy was linked to a small but statistically significant increase in prostate growth rate without measurable effects on urinary symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Urohälsan i Skövde, Skövde, Sweden; Department of Urology Region Jönköpings län, Jönkoping, Sweden.
- Department of Diagnostics and Intervention, Urology and Andrology, Umeå University, Umeå, Sweden.
- Department of Diagnostics and Intervention, Urology and Andrology, Umeå University, Umeå, Sweden. borje.ljungberg@umu.se.
- Department of Statistics, Umeå School of Business, Economics and Statistics, Umeå University, Umeå, Sweden.
Zitieren
APA
Ströberg, P., Ghaffarpour, R., Ljungberg, B., & Svensson, J. (2026). Long-term effects of testosterone therapy on prostate volume and LUTS in hypogonadal men: a retrospective study. Scandinavian Journal of Urology. https://doi.org/10.2340/sju.v61.45576
Vancouver
Ströberg P, Ghaffarpour R, Ljungberg B, Svensson J. Long-term effects of testosterone therapy on prostate volume and LUTS in hypogonadal men: a retrospective study. Scandinavian Journal of Urology. 2026. doi:10.2340/sju.v61.45576
BibTeX
@article{Strberg2026,
author = {Ströberg, Peter and Ghaffarpour, Ramin and Ljungberg, Börje and Svensson, Johan},
title = {Long-term effects of testosterone therapy on prostate volume and LUTS in hypogonadal men: a retrospective study},
journal = {Scandinavian Journal of Urology},
year = {2026},
doi = {10.2340/sju.v61.45576}
}
EUVIMED